Boston Tech
Prime Medicine Beat Beam in Gene-Editing Arbitration, and Cambridge Called It Family Therapy
Prime Medicine's July 8 Beam ruling cleared its AATD gene-editing program, giving Cambridge biotech one more extremely local way to compete.
Boston Tech
Vertex Bought Crinetics for $10 Billion, Because Boston Enjoys Expensive Homework
Vertex agreed to buy Crinetics for $10 billion on July 6, giving Boston biotech a huge endocrinology bet and a fresh test beyond cystic fibrosis.
Boston Tech
Vertex Expanded Casgevy to Age 2, and Boston's CRISPR Future Now Comes in Toddler Sizes
Vertex's July 1 FDA expansion makes Casgevy available to children ages 2 and up, a major Boston biotech milestone with real access hurdles.
Boston Tech
Flare Therapeutics Raised $85 Million to Drug Transcription Factors, Which Is Extremely Cambridge
Cambridge-based Flare Therapeutics raised $85 million on June 30 to push a first-in-class prostate cancer program after years of transcription-factor homework.
Boston Tech
Cogent Filed Its Third Bezuclastinib NDA, and Waltham Looks Weirdly Inevitable
Waltham-based Cogent filed an NDA for bezuclastinib in advanced systemic mastocytosis, turning a rare-disease bet into a serious 2026 launch race.
Boston Tech
Moderna Put CAR-T in a Vial, and Cambridge Called It a Platform
Cambridge-based Moderna unveiled mRNA-6007, an in vivo CAR-T bet on lupus and related autoimmune disease that could make cell therapy less bespoke.
Boston Tech
AbbVie Bought Apogee for $10.9 Billion Because Waltham Made Eczema Dosing Less Annoying
AbbVie is buying Waltham-based Apogee for $10.9 billion, turning a long-acting eczema antibody into Boston biotech's latest serious exit.
Boston Tech
Spero Therapeutics Won FDA Approval for an Oral Carbapenem. Cambridge Just Sent the IV Pole Home.
Spero Therapeutics won FDA approval for the first oral carbapenem in the U.S., giving Cambridge biotech a real answer to hospital-only UTI care.
Boston Tech
Agios Posted New Sickle Cell Data, and Cambridge Gets a Rare Clean Win
Agios unveiled detailed Phase 3 sickle cell data on June 13, 2026, giving Cambridge biotech a real win in a field where progress is hard to earn.
Boston Tech
Roche Bought PathAI, So Boston Tech Is Allowed to Strut for One Whole Minute
Roche is buying Boston-based PathAI for $750M upfront plus milestones, and yes, this is exactly the kind of hard-tech, health-AI win Boston should be insufferably proud of.
Startups
Helical’s $10M Seed Wants a Virtual AI Lab for Pharma — Finally, a Wet-Lab Hall Pass
Helical just raised $10M to turn bio foundation models into a virtual pharma lab. The pitch is grand, but this one might actually earn the pipettes.
Deals
IO Biotech Discovers the Strategic Alternative Is “Hiring a Banker”
IO Biotech (Nasdaq: IOBT) cost containment, workforce reduction, and the soft language of biotech distress.